# A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

> **NCT05279313** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 680 (actual)

## Conditions studied

- Attention Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Centanafadine Hydrochloride

## Key facts

- **NCT ID:** NCT05279313
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2026-04-24
- **Final completion:** 2026-04-24
- **Target enrollment:** 680 (ACTUAL)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279313, "A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT05279313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*